Please assess the completion status of the following clinical trial:

Trial Title: Assessment of the Anti-inflammatory Effects of Norflo Oro in Acute Relapses of HLA-B27 Associated Autoimmune Uveitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of HLA-B27 positive related uveitis in non- acute phase~* At least one autoimmune uveitis relapse~Exclusion Criteria:~* Use of supplements (nutraceuticals) or systemic therapy for uveitis with anti-inflammatory immunosuppressive or biological drugs within last 30 days~* Anticipated need for systemic anti-inflammatory treatment during the study~* Use of intravitreal peribulbar, sub-tenon, periocular injection in the previous 6 months~* Long-term treatment with a systemic anti-inflammatory, immune suppressant drugs~* Woman taking hormonal contraceptives, pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Norflo Oro (Type: EXPERIMENTAL): The study subject will take the entire content of one packet of Norflo (each box contains 30 packets) with meal twice per day for one year. The study subject will be evaluated in a total of three visits.
- Placebo for Norflo Oro (Type: PLACEBO_COMPARATOR): The study subject will take the entire content of one packet of Placebo (each box contains 30 packets) with meal twice per day for one year. The study subject will be evaluated in a total of three visits.

Based on this trial design, predict the completion outcome and termination type (if applicable).